Eli Lilly's modernisation plan cuts 250 jobs in France

The Fegersheim site will see a €100 million investment in new technology

picture of

Breaking News

Kiadis acquires CytoSen for synergistic immunology portfolio

CytoSen Therapeutics develops NK-cell therapy, which complements Kiadis’ T-cell therapy portfolio

Lonza: Pharma Biotech & Nutrition business performs well

The Swiss CDMO keeps 2019 outlook, expects CH 7.1 billion in sales and announces measures to mitigate headwinds ...

CPhI North America and iBIO parnership supports women in STEM

Partnership includes US$10,000 donation to fund iBIO STEM programming for girls, plus discounted rates for iBIO members ...

Molecule: Pooling the pharma industry's resources

The new software platform from Linum Labs has been designed to crowdsource funding and research, in an effort to ...

CGT Catapult brings SMEs together

Fujifilm Diosynth, Eversheds Sutherland, Mathys & Squire and Stifel gather at CGT Catapult’s first UK Advanced ...

Almac Group further expands global analytical services capability

Almac is investing in additional laboratory space at its Athlone facility in order to support microbiology and GMP ...

A new way of buying and selling APIs, additives, vitamins and excipients

Swiss Kemiex and Atradius credit insurance launch unique commodity trading platform for the pharmaceutical and ...

Catalent makes all-cash purchase of Paragon Bioservices

The CDMO will spend US$1.2 billion to purchase the viral vector producer, with further investment spent on capital ...

Protagen Protein Services and BioAnalytix merge

Combining the two US companies into one will provide global analytical services for the biopharmaceutical industry

Realising the potential of single-use technology

Today’s growing pipeline of biological drugs requires production environments that are agile and efficient

A look back at 2017 healthcare transactions

Last year, 2017, saw 2011 deals complete, with Q2 showing the strongest performance with 29.4%, followed by Q1 with 27. ...

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is ...

ReNeuron and Fosun Pharma join forces in China

For exclusive rights to its CTX and hRPC cell therapy programmes, ReNeuron will receive £6 million upfront, and ...

UK Government boosts Advanced Therapy Medicinal Products

A project has been funded by Innvoate UK to create a standardised approach to the implementation of this treatment